DOCSLIB.ORG

(2) Patent Application Publication (10) Pub. No.: US 2016/0282365A1 Gaitanaris Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(2) Patent Application Publication (10) Pub. No.: US 2016/0282365A1 Gaitanaris Et Al US 20160282365A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2016/0282365A1 Gaitanaris et al. (43) Pub. Date: Sep. 29, 2016 (54) G PROTEIN COUPLED RECEPTORS AND tion No. 10/527,265, filed on Jan. 26, 2006, now USES THEREOF abandoned, filed as application No. PCT/US03/28226 on Sep. 9, 2003. (71) Applicant: Omeros Corporation, Seattle, WA (60) Provisional application No. 60/461,329, filed on Apr. (US) 9, 2003, provisional application No. 60/409,303, filed (72) Inventors: George A. Gaitanaris, Seattle, WA on Sep. 9, 2002. (US); John E. Bergmann, Yonkers, NY Publication Classification (US); Alexander Gragerov, Seattle, WA (US); John Hohmann, Seattle, WA (51) Int. Cl. (US); Fusheng Li, Seattle, WA (US); G0IN 33/74 (2006.01) Linda Madisen, Seattle, WA (US); (52) U.S. CI. Kellie L. McIlwain, Washington, DC CPC ......... G0IN 33/74 (2013.01); G0IN 2333/726 (US); Maria N. Pavlova, Seattle, WA (2013.01); G0IN 2500/04 (2013.01); G0IN (US); Demetri Vassilatis, Seattle, WA (US); Hongkui Zeng, Shoreline, WA 2500/10 (2013.01) (US) (57) ABSTRACT The present invention provides GPCR polypeptides and (21) Appl. No.: 15/007,805 polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypep (22) Filed: Jan. 27, 2016 tides and polynucleotides are useful, for example, in meth ods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying com Related U.S. Application Data pounds (e.g., agonists or antagonists) using the GPCR (63) Continuation of application No. 13/796,312, filed on polypeptides and polynucleotides of the invention, and for Mar. 12, 2013, now abandoned, which is a continu treating conditions associated with GPCR dysfunction with ation of application No. 12/970,094, filed on Dec. 16, the GPCR polypeptides, polynucleotides, or identified com 2010, now abandoned, which is a continuation of pounds. The invention also provides diagnostic assays for application No. 12/243,731, filed on Oct. 1, 2008, detecting diseases or disorders associated with inappropriate now abandoned, which is a continuation of applica GPCR activity or levels. Patent Application Publication Sep. 29, 2016 Sheet 1 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 2 of 35 US 2016/0282365 A1 . seloads Patent Application Publication Sep. 29, 2016 Sheet 3 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 4 of 35 US 2016/0282365 A1 ; ºf 3: ...; º; # ºf 3 × 3 × 3 × . º. ºf 3 Patent Application Publication Sep. 29, 2016 Sheet 5 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 6 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 7 of 35 US 2016/0282365 A1 § º $ $ $ & # 3 : Patent Application Publication Sep. 29, 2016 Sheet 8 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 9 of 35 US 2016/0282365 A1 nhdae wwwx te § § ######## Patent Application Publication Sep. 29, 2016 Sheet 10 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 11 of 35 US 2016/0282365A1 S& wº SD Ll Patent Application Publication Sep. 29, 2016 Sheet 12 of 35 US 2016/0282365 A1 ############## TI Patent Application Publication Sep. 29, 2016 Sheet 13 of 35 US 2016/0282365A1 . Patent Application Publication Sep. 29, 2016 Sheet 14 of 35 US 2016/0282365A1 : Patent Application Publication Sep. 29, 2016 Sheet 15 of 35 US 2016/0282365A1 : Patent Application Publication Sep. 29, 2016 Sheet 16 of 35 US 2016/0282365A1 FIG. 1P Patent Application Publication Sep. 29, 2016 Sheet 17 of 35 US 2016/0282365 A1 isaepidodones rt ritºrs tº ºr ritºr in tº rars tº tº *************~~~~, º (N Ll Patent Application Publication Sep. 29, 2016 Sheet 18 of 35 US 2016/0282365 A1 (guoko)vssero Patent Application Publication Sep. 29, 2016 Sheet 19 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 20 of 35 US 2016/0282365 A1 ~~~~~x~~~~..…~~zzzzzzzº,…….……..:…, &~~~~~~~~~~~~--~~~~.~~~~;~~ -...& Patent Application Publication Sep. 29, 2016 Sheet 21 of 35 US 2016/0282365 A1 eurotran mitter | ~~~~~..,,,,,.,,, ********×?. ---********************------~~~);&&&&&&&&&&&&&&&&), Patent Application Publication Sep. 29, 2016 Sheet 23 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 24 of 35 US 2016/0282365 A1 ossero Patent Application Publication Sep. 29, 2016 Sheet 25 of 35 US 2016/0282365A1 FIG. 2A F|G. 2B F|G. 2D FIG. 2E FIG. 2G FIG. 2H FIG. 2. Patent Application Publication Sep. 29, 2016 Sheet 26 of 35 US 2016/0282365 A1 id: snuelethodºº, Patent Application Publication Sep. 29, 2016 Sheet 27 of 35 US 2016/0282365A1 ; i : Patent Application Publication Sep. 29, 2016 Sheet 28 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 29 of 35 US 2016/0282365A1 Patent Application Publication Sep. 29, 2016 Sheet 31 of 35 US 2016/0282365 A1 Patent Application Publication Sep. 29, 2016 Sheet 33 of 35 US 2016/0282365A1 & GPR85 – SIH:T1 — To xxxxxxxxxxxxxº~& & § Genotype | jºxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx, F|G. 7A § § GPR85 – Baseline Temperature § § § § XS & §& § §& i & >s § &§ § i X I & & § Xs X X X X X X X §§§ X X X X X X X X X X X X X X X X X X X X X X X X X X X X Genotype SX §X. x **************. & FIG. 7B Patent Application Publication Sep. 29, 2016 Sheet 34 of 35 US 2016/0282365A1 Patent Application Publication Sep. 29, 2016 Sheet 35 of 35 US 2016/0282365A1 es-s 1.0 & & -10 ; ; - 1 - 5 &ssssssssssss-->º ~ Treatment day & F|G. 9A &xxxxxxxxx GPR85 — Ethanol Tolerance 1.2 &XXXXXXXXXº 1 &^********* ºccº | 0. 8 i s 0. 6 & 0. 4 s 0. 2 O Genotype US 2016/0282365 A1 Sep. 29, 2016 G PROTEIN COUPLED RECEPTORS AND models, and modulating compounds for use in the treatment USES THEREOF and diagnosis of a wide variety of disorders and diseases. CROSS-REFERENCES TO RELATED SUMMARY OF THE INVENTION APPLICATIONS [0007] The present invention provides GPCR polypep [0001] This application is continuation of pending U.S. tides and polynucleotides, recombinant materials, and trans patent application Ser. No. 13/796,312, filed Mar 12, 2013, genic mice, as well as methods for their production. The which is a continuation of U.S. patent application Ser. No. polypeptides and polynucleotides are useful, for example, in 12/970,094, filed Dec. 16, 2010, now abandoned, which is a methods of diagnosis and treatment of diseases and disor continuation of U.S. patent application Ser. No. 12/243,731, ders. The invention also provides methods for identifying filed Oct. 1, 2008, now abandoned, which is a continuation compounds (e.g., agonists or antagonists) using the GPCR of U.S. patent application Ser. No. 10/527,265, filed Jan. 26, polypeptides and polynucleotides of the invention, and for 2006, now abandoned, which is a U.S. national stage appli treating conditions associated with GPCR dysfunction with cation of PCT Patent Application No. PCT/US03/28226, the GPCR polypeptides, polynucleotides, or identified com filed Sep. 9, 2003, which claims the benefit under 35 U.S.C. pounds. The invention also provides diagnostic assays for $119(e) of U.S. Provisional Patent Application No. 60/409, detecting diseases or disorders associated with inappropriate 303, filed Sep. 9, 2002, and U.S. Provisional Patent Appli GPCR activity or levels. cation No. 60/461,329, filed Apr. 9, 2003, where all of the [0008] In one aspect, the invention features a variety of above applications are incorporated herein by reference in substantially pure GPCR polypeptides. Such polypeptides their entireties. include: (a) polypeptides including a polypeptide sequence having at least 90%, 95%, 97%, 98%, or 99% identity to a STATEMENT REGARDING SEQUENCE polypeptide listed in Table 2; (b) polypeptides that include LISTING a polypeptide listed in Table 2; (c) polypeptides having at least 90%, 95%, 97%, 98%, or 99% sequence identity to a [0002] The Sequence Listing associated with this applica polypeptide listed in Table 2; and (d) polypeptides listed in tion is provided in text format in lieu of a paper copy, and Table 2. is hereby incorporated by reference into the specification. [0009] Polypeptides of the present invention also include The name of the text file containing the Sequence Listing is variants of the aforementioned polypeptides, including all NG_1_0058 US5_SEQUENCELISTING..txt. The text file allelic forms and splice variants. Such polypeptides vary is 4,999 KB, was created on Jan. 26, 2016, and is being from the reference polypeptide by insertions, deletions, and submitted electronically via EFS-Web, concurrent with the substitutions that may be conservative or non-conservative, filing of the specification. or any combination thereof. Particularly desirable variants are those in which several, for instance from 50 to 30, from BACKGROUND OF THE INVENTION 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 [0003] The invention relates to the fields of medicine and to 2, or from 2 to 1 amino acids are inserted, substituted, or drug discovery. deleted, in any combination. [0004] Mammalian G protein coupled receptors (GPCRs) [0010] Polypeptides of the present invention also include constitute a superfamily of diverse proteins with thousands polypeptides that include an amino acid sequence having at of members. GPCRs act as receptors for a multitude of least 30, 50, or 100 contiguous amino acids from any of the different signals. Chemosensory GPCRs (csOPCR) are polypeptides listed in Table 2. Polypeptides of the invention receptors for sensory signals of external origin that are are desirably biologically active or are antigenic or immu sensed as odors, pheromones, or tastes. Most other GPCRs nogenic in an animal, especially in a human.
Load more

Recommended publications
  • Supranuclear and Internuclear Ocular Motility Disorders
    CHAPTER 19 Supranuclear and Internuclear Ocular Motility Disorders David S. Zee and David Newman-Toker OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN OCULAR MOTOR SYNDROMES CAUSED BY LESIONS OF THE MEDULLA THE SUPERIOR COLLICULUS Wallenberg’s Syndrome (Lateral Medullary Infarction) OCULAR MOTOR SYNDROMES CAUSED BY LESIONS OF Syndrome of the Anterior Inferior Cerebellar Artery THE THALAMUS Skew Deviation and the Ocular Tilt Reaction OCULAR MOTOR ABNORMALITIES AND DISEASES OF THE OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN BASAL GANGLIA THE CEREBELLUM Parkinson’s Disease Location of Lesions and Their Manifestations Huntington’s Disease Etiologies Other Diseases of Basal Ganglia OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN THE PONS THE CEREBRAL HEMISPHERES Lesions of the Internuclear System: Internuclear Acute Lesions Ophthalmoplegia Persistent Deficits Caused by Large Unilateral Lesions Lesions of the Abducens Nucleus Focal Lesions Lesions of the Paramedian Pontine Reticular Formation Ocular Motor Apraxia Combined Unilateral Conjugate Gaze Palsy and Internuclear Abnormal Eye Movements and Dementia Ophthalmoplegia (One-and-a-Half Syndrome) Ocular Motor Manifestations of Seizures Slow Saccades from Pontine Lesions Eye Movements in Stupor and Coma Saccadic Oscillations from Pontine Lesions OCULAR MOTOR DYSFUNCTION AND MULTIPLE OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN SCLEROSIS THE MESENCEPHALON OCULAR MOTOR MANIFESTATIONS OF SOME METABOLIC Sites and Manifestations of Lesions DISORDERS Neurologic Disorders that Primarily Affect the Mesencephalon EFFECTS OF DRUGS ON EYE MOVEMENTS In this chapter, we survey clinicopathologic correlations proach, although we also discuss certain metabolic, infec- for supranuclear ocular motor disorders. The presentation tious, degenerative, and inflammatory diseases in which su- follows the schema of the 1999 text by Leigh and Zee (1), pranuclear and internuclear disorders of eye movements are and the material in this chapter is intended to complement prominent.
    [Show full text]
  • Retina and Neuro Ophthalmology
    Name : …………………………………………………………… Roll No. : ………………………………………………………… Invigilator's Signature : ……………………………………….. CS/B.OPTM/SEM-5/BO-504/2010-11 2010-11 OCULAR DISEASE - II POSTERIOR SEGMENT ( RETINA & NEURO-OPHTHALMOLOGY ) Time Allotted : 3 Hours Full Marks : 70 The figures in the margin indicate full marks. Candidates are required to give their answers in their own words as far as practicable. GROUP – A ( Multiple Choice Type Questions ) 1. Choose the correct alternatives for any ten of the following : 10 × 1 = 10 i) Which is not an important diagnostic criterion of giant cell arteritis ? http://www.makaut.com/ a) ESR > 70 mm/hour b) C-reactive protein > 2·45 mg/dl c) Jaw caludication d) Neck pain. ii) Unilateral blindness in a male child with massive exudation under the retina is most likely a case of a) Coat's disease b) Retinoblastoma c) Sturge-Weber syndrome d) Louis-Bar's syndrome. 5323 [ Turn over http://www.makaut.com/ CS/B.OPTM/SEM-5/BO-504/2010-11 iii) A retinal detachment patient mostly complains of a) pain b) good vision c) flashes and floaters d) diplopia. iv) In myasthenia gravis, during a diagnostic test, we use a drug called a) Piperazine citrate b) Azathioprim c) Edrophonium d) Carbamazepine. v) Sillicone oil is a/an a) aqueous substitute b) lens substitute c) vitreous substitute d) artificial lens. vi) In retinoblastoma, if the microscopical examination shows Flexner-Wintersteiner rosettes, it is considered to be a) highly malignant b) less malignant c) not malignant d) none of these. vii) Dyschromatopsia is the term for defective a) day vision b) night vision http://www.makaut.com/ c) colour vision d) light brightness sensitivity.
    [Show full text]
  • A Case of Multiple Sclerosis Presenting As Eight and Half Syndrome
    Online Journal of Health and Allied Sciences Peer Reviewed, Open Access, Free Online Journal Published Quarterly : Mangalore, South India : ISSN 0972-5997 This work is licensed under a Volume 11, Issue 4; Oct-Dec 2012 Creative Commons Attribution- No Derivative Works 2.5 India License Case Report: A Case of Multiple Sclerosis Presenting as Eight and Half Syndrome. Authors Rajiv Raina, Professor, Madan Kaushik, Assistant Professor, Sanjay K Mahajan, Assistant Professor, Sushil Raghav, Senior Resident, Sharathbabu NM, Junior Resident, Dept. of Medicine, Indira Gandhi Medical College, Shimla. Address for Correspondence Dr. Sharathbabu NM, Junior Resident, Dept. of Medicine, Indira Gandhi Medical College, Shimla, India. E-mail: [email protected] Citation Raina R, Kaushik M, Mahajan SK, Raghav S, Sharathbabu NM. A Case of Multiple Sclerosis Presenting as Eight and Half Syndrome. Online J Health Allied Scs. 2012;11(4):15. Available at URL: http://www.ojhas.org/issue44/2012-4-15.html Open Access Archives http://cogprints.org/view/subjects/OJHAS.html http://openmed.nic.in/view/subjects/ojhas.html Submitted: Dec 5, 2012; Accepted: Jan 7, 2013; Published: Jan 25, 2013 Abstract: Multiple sclerosis (MS) is a chronic disease spinal cord. MRI showed hyperintensities on T2 weighted characterized by inflammation, demyelination, gliosis images oriented perpendicular to the ventricular surface, (scarring), and neuronal loss; the course can be relapsing- corresponding to the pathologic pattern of perivenous remitting or progressive. Manifestations of MS vary from a demyelination (Dawson's fingers) and hyperintensities in the benign illness to a rapidly evolving and incapacitating dorsal tegmentum of caudal pons(Fig. 3a & 3b). Patient was disease requiring profound lifestyle adjustments.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Formula Name Category Description Qualifying
    Memorandum #17-079 TO: WIC Regional Directors WIC Local Agency Directors FROM: Amanda Hovis, Director Nutrition Education/Clinic Services Unit Nutrition Services Section DATE: August 4, 2017 SUBJECT: Revised Formula Approval Resources Posted The formula approval resources have been revised to reflect the recent clinic formula table changes and will be posted to the DSHS WIC website. You will be able view them at the following link under “Formula Approval Resources” once they are posted. http://www.dshs.texas.gov/wichd/nut/foods-nut.shtm The following documents have been revised for July, 2017. Presently, they are attached to this memo as PDF files. 1. Texas WIC Formulary 2. Formula Code List 3. Texas WIC Formula Maximum Quantity Table 4. Nutrition Assessment Requirements Guide If you have questions or require additional information, contact Pat Koym, Formula Specialist, at [email protected] or 512-341-4578. This institution is an equal opportunity provider TEXAS WIC FORMULARY AND MEDICAL REASONS FOR ISSUANCE JULY 2017 Formula Category Description Qualifying Conditions Staff Instructions - May issue for 1 cert Manufacturer Name period unless otherwise indicated Alfamino Infant Elemental 20 cal/oz when mixed 1 scoop to 1 oz 1) Malabsorption syndrome Formula history required. Nestle water; hypoallergenic amino acid 2) GI impairment When requested for food allergy - a failed trial of a protein based elemental. 43% of fat is MCT 3) GER/GERD hydrolysate (Extensive HA, Nutramigen, Alimentum, or oil; Similar to Elecare DHA/ARA, 4) Food allergies (cow's milk, soy or Pregestimil) is recommended before issuing unless medically Neocate DHA/ARA and PurAmino.
    [Show full text]
  • Eyes and Stroke: the Visual Aspects of Cerebrovascular Disease
    Open Access Review Stroke Vasc Neurol: first published as 10.1136/svn-2017-000079 on 6 July 2017. Downloaded from Eyes and stroke: the visual aspects of cerebrovascular disease John H Pula,1 Carlen A Yuen2 To cite: Pula JH, Yuen CA. Eyes ABSTRACT to the LGBs,1 5 6 the terminal anastomosis is and stroke: the visual aspects of A large portion of the central nervous system is dedicated vulnerable to ischaemia.7 Optic radiations cerebrovascular disease. Stroke to vision and therefore strokes have a high likelihood 2017; : originate from the lateral geniculate nucleus and Vascular Neurology 2 of involving vision in some way. Vision loss can be the e000079. doi:10.1136/svn- (LGN) and are divided into superior, inferior, 2017-000079 most disabling residual effect after a cerebral infarction. and central nerve fibres. The optic radiations Transient vision problems can likewise be a harbinger of are predominantly supplied by the posterior stroke and prompt evaluation after recognition of visual and middle cerebral arteries1 and the AChA.6 Received 12 March 2017 symptoms can prevent future vascular injury. In this review, Inferior fibres, known as Meyer’s Loop,6 travel Revised 30 May 2017 we discuss the visual aspects of stroke. First, anatomy and Accepted 2 June 2017 the vascular supply of the visual system are considered. to the temporal lobe, while the superior and Published Online First Then, the different stroke syndromes which involve vision central nerve fibre bundles travel to the pari- 6 July 2017 1 are discussed. Finally, topics involving the assessment, etal lobes. The termination of optic radia- prognosis, treatment and therapeutic intervention of vision- tions is located in the visual striate cortex (V1) specific stroke topics are reviewed.
    [Show full text]
  • GAZE and AUTONOMIC INNERVATION DISORDERS Eye64 (1)
    GAZE AND AUTONOMIC INNERVATION DISORDERS Eye64 (1) Gaze and Autonomic Innervation Disorders Last updated: May 9, 2019 PUPILLARY SYNDROMES ......................................................................................................................... 1 ANISOCORIA .......................................................................................................................................... 1 Benign / Non-neurologic Anisocoria ............................................................................................... 1 Ocular Parasympathetic Syndrome, Preganglionic .......................................................................... 1 Ocular Parasympathetic Syndrome, Postganglionic ........................................................................ 2 Horner Syndrome ............................................................................................................................. 2 Etiology of Horner syndrome ................................................................................................ 2 Localizing Tests .................................................................................................................... 2 Diagnosis ............................................................................................................................... 3 Flow diagram for workup of anisocoria ........................................................................................... 3 LIGHT-NEAR DISSOCIATION .................................................................................................................
    [Show full text]
  • Conjoint Ophthalmology Scientific Conference (COSC 2017)
    Artwork for the 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) Logo COSC 2017 (designed by Dr Aliff Irwan Cheong) The logo symbolizes: 1. “C” represents as the whole eye, and its fluidic and wave like angle shape, exhibit the conference main theme “Angles and Curves”. The inferior tail of the “C” crosses and twist towards the word 2017 represents the conference aim in achieving advancement in Ophthalmology especially in Malaysia. 2. “O” represents the cornea and pupil – exhibit the specialty of interest : Glaucoma & Cornea. 3. “7” signify in RED is a hallmark of conference by COSC 2017. 4. BLUE – Theme color for conference and shown with the year its being held 5. BLACK – Second theme color for conference and shown in the other structure of interest Front Cover Artwork (designed by Dr Tan Li Mun) 1. Image of Cornea and Kuala Lumpur City Centre (KLCC) - Signifies the theme of our conjoint "Angles and Curves" and the location of our event held in Kuala Lumpur 2. Image of Pupil and Iris on the background - Signifies the other parts of anterior segment of the eye. ii Foreword The 7th Conjoint Ophthalmology Scientific Conference (COSC 2017) was held on 15-17 September 2017 at the Pullman Kuala Lumpur Bangsar, Kuala Lumpur. These Scientific Conferences have been held by the Malaysian Universities Conjoint Committee of Ophthalmology every year since 2011, and the theme for this year‟s meeting was „Angles and Curves - New Perspectives on Glaucoma and Cornea Management‟. The programme consisted of workshops, lectures and case discussions conducted by expert international and local speakers, and updated participants on latest developments in the two exciting fields.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris Et Al
    US 2006O134109A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0134109 A1 Gaitanaris et al. (43) Pub. Date: Jun. 22, 2006 (54) GPROTEIN COUPLED RECEPTORS AND in-part of application No. 60/461.329, filed on Apr. 9. USES THEREOF 2003. (75) Inventors: George A. Gaitanaris, Seattle, WA Publication Classification (US); John E. Bergmann, Mercer Island, WA (US); Alexander Gragerov, (51) Int. Cl. Seattle, WA (US); John Hohmann, La CI2O I/68 (2006.01) Conner, WA (US); Fusheng Li, Seattle, C7H 2L/04 (2006.01) WA (US); Linda Madisen, Seattle, WA (US); Kellie L. McIlwain, Renton, WA CI2P 2/06 (2006.01) (US); Maria N. Pavlova, Seattle, WA A 6LX 39/395 (2006.01) (US); Demitri Vassilatis, Seattle, WA C07K I4/705 (2006.01) (US); Hongkui Zeng, Shoreline, WA (52) U.S. Cl. ......................... 424/143.1: 435/6: 435/69.1; 435/320.1; 435/325; 530/350; (US) 536/23.5 Correspondence Address: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC (57) ABSTRACT 701 FIFTHAVE SUTE 63OO The present invention provides GPCR polypeptides and SEATTLE, WA 98104-7092 (US) polynucleotides, recombinant materials, and transgenic (73) Assignee: Nura Inc., Seattle, WA (US) mice, as well as methods for their production. The polypep tides and polynucleotides are useful, for example, in meth (21) Appl. No.: 10/527,265 ods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying com (22) PCT Fed: Sep. 9, 2003 pounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for (86) PCT No.: PCT/USO3/28226 treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified com Related U.S.
    [Show full text]
  • Juxtaposition of One and a Half Syndrome with Pseudo One and a Half Syndrome
    Case Report Annals of Clinical Case Reports Published: 11 Dec, 2018 Juxtaposition of One and a Half Syndrome with Pseudo One and a Half Syndrome Edward Chai, Sirac Cardoza*, Ivan Rosado, Prabjhot Manes, Haidy Rivero and Adam Bernstein Department of Neurology, The Brooklyn Hospital Center, USA Abstract Conjugate gaze palsy with contralateral internuclear ophthalmoplegia or One and a Half Syndrome, is a rare neurological condition that was originally described in 1967. The authors present two patients, one with true one and a half syndrome caused by a CVA and another with pseudo one and a half syndrome caused by myasthenia gravis. Clinical presentation of these syndromes can be similar with minute differences appreciated on physical exam; however, the clinical relevance is quite large as the management is entirely different. Abbreviations INO: Internuclear Ophthalmoplegia; MLF: Medial Longitudinal Fasciculus; PPRF: Para Median Pontine Reticular Formation; CT: Computed Tomography; MRI: Magnetic Resonance Imaging Introduction “One and a half syndrome” was originally described in 1967 as conjugate gaze palsy with a contralateral Internuclear Ophthalmoplegia (INO) [1]. The syndrome is typically due to a single unilateral lesion of the Paramedian Pontine Reticular Formation (PPRF) or the abducens nucleus, and the adjacent Medial Longitudinal Fasciculus (MLF) [2,3]. Damage to the former manifests as the ipsilateral conjugate gaze palsy. Damage to the latter interrupts the internuclear fibers crossing midline to the contralateral medial rectus resulting in contralateral adduction failure on opposite gaze [2]. The side of the INO refers to the direction in which the previous adductor palsy manifests and is contralateral to the gaze palsy.
    [Show full text]
  • Catabolism of the Carbon Skeletons of Amino Acids
    Bio. 2. ASPU. Lectu.3. Prof. Dr. F. ALQuobaili Catabolism of the Carbon Skeletons of Amino Acids • Biomedical Importance ‐ The metabolic diseases or "inborn errors of metabolism" associated with conversion of the carbon skeletons of the common L ‐‐amino acids to amphibolic intermediates can result in irreversible brain damage and .(ﺍﻟﻭﻓﺎﺓ) early mortality ‐ Prenatal or early postnatal detection and timely initiation of treatment thus are essential. Almost all states conduct screening tests for up to as many as 30 metabolic diseases. ‐ The best screening tests use tandem mass spectrometry to detect, in a few drops of neonate blood, catabolites suggestive of a metabolic defect. ‐ Treatment consists primarily of feeding diets low in the amino acids whose catabolism is impaired. • Transamination Typically Initiates Amino Acid Catabolism Removal of ‐amino nitrogen by transamination is the first catabolic reaction of amino acids except for proline, hydroxyproline, threonine, and lysine. The hydrocarbon skeleton that remains is then degraded to amphibolic intermediates. • Asparagine, Aspartate, Glutamine, and Glutamate All four carbons of asparagine and aspartate form oxaloacetate. Analogous reactions convert glutamine and glutamate to ‐ ketoglutarate. No metabolic defects are associated with the catabolism of these four amino acids. • Proline The catabolism of proline takes place in mitochodria. Since proline does not participate in transamination, the nitrogen of this imino acid is retained throughout its oxidation to 1‐ pyrolline‐5‐carboxylate, ring opening to glutamate‐‐ semialdehyde, and oxidation to glutamate, and is only removed during transamination of glutamate to ‐ketoglutarate. There are two metabolic disorders of proline catabolism. Both types are inherited as autosomal recessive traits, and are consistent with a normal adult life.
    [Show full text]
  • 23 Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism
    23 Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism Georg F. Hoffmann 23.1 Introduction – 295 23.2 Hyperlysinemia/Saccharopinuria – 295 23.2.1 Clinical Presentation – 295 23.2.2 Metabolic Derangement – 295 23.2.3 Genetics – 296 23.2.4 Diagnostic Tests – 296 23.2.5 Treatment and Prognosis – 296 23.3 Hydroxylysinuria – 296 23.4 2-Amino-/2-Oxo-Adipic Aciduria – 296 23.4.1 Clinical Presentation – 296 23.4.2 Metabolic Derangement – 296 23.4.3 Genetics – 296 23.4.4 Diagnostic Tests – 296 23.4.5 Treatment and Prognosis – 297 23.5 Glutaric Aciduria Type I (Glutaryl-CoA Dehydrogenase Deficiency) – 297 23.5.1 Clinical Presentation – 297 23.5.2 Metabolic Derangement – 297 23.5.3 Genetics – 300 23.5.4 Diagnostic Tests – 300 23.5.5 Treatment and Prognosis – 301 23.6 L-2-Hydroxyglutaric Aciduria – 302 23.6.1 Clinical Presentation – 302 23.6.2 Metabolic Derangement – 303 23.6.3 Genetics – 303 23.6.4 Diagnostic Tests – 303 23.6.5 Treatment and Prognosis – 303 23.7 D-2-Hydroxyglutaric Aciduria – 303 23.7.1 Clinical Presentation – 303 23.7.2 Metabolic Derangement – 303 23.7.3 Genetics – 303 23.7.4 Diagnostic Tests – 304 23.7.5 Treatment and Prognosis – 304 23.8 N-Acetylaspartic Aciduria (Canavan Disease) – 304 23.8.1 Clinical Presentation – 304 23.8.2 Metabolic Derangement – 304 23.8.3 Genetics – 304 23.8.4 Diagnostic Tests – 304 23.8.5 Treatment and Prognosis – 305 References – 305 294 Chapter 23 · Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism Catabolism of Lysine, Hydroxylysine, and Tryptophan Lysine, hydroxylysine and tryptophan are degraded with- otide (FAD) and hence to the respiratory chain (.
    [Show full text]